

Potenziell maligne Läsionen der Mundschleimhaut

Dr. Dr. Maximilian Krüger, Dr. Paul Römer

ZMK 5/2023 (39), 220-227

1. Bray, F., et al., *Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries*. CA Cancer J Clin, 2018. **68**(6): p. 394-424.
2. Panarese, I., et al., *Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route*. Expert Rev Anticancer Ther, 2019. **19**(2): p. 105-119.
3. Cancer, I.A.f.R.o., *Global Cancer Observatory*, <https://gco.iarc.fr/>. (abgerufen 11. März, 2023), 2023.
4. Jansen, L., et al., *[Oral and pharyngeal cancer: incidence, mortality, and survival in Germany]*. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz, 2021. **64**(8): p. 941-950.
5. Wolff, K.D., M. Follmann, and A. Nast, *The diagnosis and treatment of oral cavity cancer*. Dtsch Arztebl Int, 2012. **109**(48): p. 829-35.
6. Kaemmerer, P., et al., *Diagnostik potenziell maligner Mundschleimhautveränderungen in der Zahnarztpraxis*. wissen kompakt, 2017. **11**.
7. Blatt, S., et al., *Diagnosing oral squamous cell carcinoma: How much imaging do we really need? A review of the current literature*. J Craniomaxillofac Surg, 2016. **44**(5): p. 538-49.
8. Chamoli, A., et al., *Overview of oral cavity squamous cell carcinoma: Risk factors, mechanisms, and diagnostics*. Oral Oncol, 2021. **121**: p. 105451.
9. Krüger, M., et al., *The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: A retrospective analysis of 88 patients and literature overview*. Journal of Cranio-Maxillofacial Surgery, 2014. **42**(7): p. 1506-1514.
10. Marsh, D., et al., *Stromal features are predictive of disease mortality in oral cancer patients*. J Pathol, 2011. **223**(4): p. 470-81.
11. Seoane-Romero, J.M., et al., *Factors related to late stage diagnosis of oral squamous cell carcinoma*. Med Oral Patol Oral Cir Bucal, 2012. **17**(1): p. e35-40.
12. Brocklehurst, P., et al., *Screening programmes for the early detection and prevention of oral cancer*. Cochrane Database Syst Rev, 2013(11): p. CD004150.
13. Mello, F.W., et al., *Prevalence of oral potentially malignant disorders: A systematic review and meta-analysis*. J Oral Pathol Med, 2018. **47**(7): p. 633-640.
14. AWMF, *S3-Leitlinie Diagnostik und Therapie des Mundhöhlenkarzinoms, Version 3.0 - März 2021*. 2021.
15. AWMF, *Sk2-Leitlinie Diagnostik und Management von Vorläuferläsionen des oralen Plattenepithelkarzinoms in der Zahn-, Mund- und Kieferheilkunde*. 2019.
16. Reichart, P.A., *Oral mucosal lesions in a representative cross-sectional study of aging Germans*. Community Dent Oral Epidemiol, 2000. **28**(5): p. 390-8.
17. Reichart, P., *Orale Leukoplakie / Erythroplakie. Stellungnahme der Deutschen Gesellschaft für Zahn-, Mund- und Kieferheilkunde*. Deutsche Gesellschaft für Zahn-, Mund- und Kieferheilkunde, 2007.
18. El-Naggar, A., et al., *WHO Classification of Tumours, 4th Edition, Volume 9*. IARC Press, 2017. **9**.
19. El-Naggar, A.K., et al., *The fourth edition of the head and neck World Health Organization blue book: editors' perspectives*. Hum Pathol, 2017. **66**: p. 10-12.
20. Felix, D., J. Luker, and C. Sully, *Oral Medicine: 6. White Lesions*. DentalUpdate, 2013.
21. Micheelis, W. and E. Reich, *Dritte Deutsche Mundgesundheitsstudie (DMS III)*. 1997.

22. Splieth, C.H., et al., *Prevalence of oral mucosal lesions in a representative population*. Quintessence Int, 2007. **38**(1): p. 23-9.
23. Kindler, S., et al., *Prevalence and risk factors of potentially malignant disorders of the mucosa in the general population: Mucosa lesions a general health problem?* Ann Anat, 2021. **237**: p. 151724.
24. Reichart, P. and H. Philipsen, *Proliferative verruköse Leukoplakie: Bericht über 5 Fälle*. Mund-, Kiefer-und Gesichtschirurgie, 2003. **7**: p. 164-170.
25. El Nagggar, A. and P. Reichart, *Proliferative verrucous leukoplakia and precancerous conditions*. Pathology and genetics head and neck tumours, 2005.
26. Thiem, D.G.E., et al., *Semiquantifiable angiogenesis parameters in association with the malignant transformation of oral leukoplakia*. Journal of Oral Pathology & Medicine, 2017. **46**(9): p. 710-716.
27. Villa, A. and S.B. Woo, *Leukoplakia-A Diagnostic and Management Algorithm*. J Oral Maxillofac Surg, 2017. **75**(4): p. 723-734.
28. Llewellyn, C.D., N.W. Johnson, and K.A. Warnakulasuriya, *Risk factors for oral cancer in newly diagnosed patients aged 45 years and younger: a case-control study in Southern England*. J Oral Pathol Med, 2004. **33**(9): p. 525-32.
29. Reibel, J., *Tobacco or oral health*. Bull World Health Organ, 2005. **83**(9): p. 643.
30. Silverman, S., Jr., M. Gorsky, and F. Lozada, *Oral leukoplakia and malignant transformation. A follow-up study of 257 patients*. Cancer, 1984. **53**(3): p. 563-8.
31. Reichart, P.A. and H.P. Philipsen, *Oral erythroplakia--a review*. Oral Oncol, 2005. **41**(6): p. 551-61.
32. Aguirre-Urizar, J.M., I. Lafuente-Ibanez de Mendoza, and S. Warnakulasuriya, *Malignant transformation of oral leukoplakia: Systematic review and meta-analysis of the last 5 years*. Oral Dis, 2021. **27**(8): p. 1881-1895.
33. McCormick, N.J., P.J. Thomson, and M. Carrozzo, *The Clinical Presentation of Oral Potentially Malignant Disorders*. Prim Dent J, 2016. **5**(1): p. 52-63.
34. Warnakulasuriya, S., et al., *Oral potentially malignant disorders: A consensus report from an international seminar on nomenclature and classification, convened by the WHO Collaborating Centre for Oral Cancer*. Oral Dis, 2021. **27**(8): p. 1862-1880.
35. Jacob, B.J., et al., *Betel quid without tobacco as a risk factor for oral precancers*. Oral Oncol, 2004. **40**(7): p. 697-704.
36. Hashibe, M., et al., *Chewing tobacco, alcohol, and the risk of erythroplakia*. Cancer Epidemiol Biomarkers Prev, 2000. **9**(7): p. 639-45.
37. Hashibe, M., et al., *Socioeconomic status, lifestyle factors and oral premalignant lesions*. Oral Oncol, 2003. **39**(7): p. 664-71.
38. Kumari, P., P. Debta, and A. Dixit, *Oral Potentially Malignant Disorders: Etiology, Pathogenesis, and Transformation Into Oral Cancer*. Front Pharmacol, 2022. **13**: p. 825266.
39. Yang, S.W., et al., *Outcome of excision of oral erythroplakia*. Br J Oral Maxillofac Surg, 2015. **53**(2): p. 142-7.
40. Schilling, L. and T. Vogt, *[Lichen ruber planus : Better understanding, better treatment!]*. Hautarzt, 2018. **69**(2): p. 100-108.
41. Nogueira, P.A., S. Carneiro, and M. Ramos-e-Silva, *Oral lichen planus: an update on its pathogenesis*. Int J Dermatol, 2015. **54**(9): p. 1005-10.
42. Lodi, G., et al., *Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis*. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 2005. **100**(1): p. 40-51.
43. Remmerbach, T.W., *Potentially malignant disorders of the oral mucosa*. Deutsche Zahnärztliche Zeitschrift (DZZ), 2012. **Ausgabe 10/2012**.
44. Farhi, D. and N. Dupin, *Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies*. Clin Dermatol, 2010. **28**(1): p. 100-8.
45. Ramos-e-Silva, M., C. Jacques, and S.C. Carneiro, *Premalignant nature of oral and vulval lichen planus: facts and controversies*. Clin Dermatol, 2010. **28**(5): p. 563-7.

46. Eisen, D., et al., *Number V Oral lichen planus: clinical features and management*. Oral Dis, 2005. **11**(6): p. 338-49.
47. Ismail, S.B., S.K. Kumar, and R.B. Zain, *Oral lichen planus and lichenoid reactions: etiopathogenesis, diagnosis, management and malignant transformation*. J Oral Sci, 2007. **49**(2): p. 89-106.
48. Höller, S. and I. Hitz Lindenmüller, *Oraler Lichen planus*. Der MKG-Chirurg, 2018. **11**(1): p. 4-11.
49. Alrashdan, M.S., N. Cirillo, and M. McCullough, *Oral lichen planus: a literature review and update*. Arch Dermatol Res, 2016. **308**(8): p. 539-51.
50. Scully, C. and M. Carrozzo, *Oral mucosal disease: Lichen planus*. Br J Oral Maxillofac Surg, 2008. **46**(1): p. 15-21.
51. Sankaranarayanan, R., et al., *Effect of screening on oral cancer mortality in Kerala, India: a cluster-randomised controlled trial*. Lancet, 2005. **365**(9475): p. 1927-33.
52. Sankaranarayanan, R., et al., *Long term effect of visual screening on oral cancer incidence and mortality in a randomized trial in Kerala, India*. Oral Oncol, 2013. **49**(4): p. 314-21.
53. Warnakulasuriya, S. and A.R. Kerr, *Oral Cancer Screening: Past, Present, and Future*. J Dent Res, 2021. **100**(12): p. 1313-1320.
54. Walsh, T., et al., *Clinical assessment for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults*. Cochrane Database Syst Rev, 2021. **12**: p. CD010173.
55. Metzger, K., et al., *Treatment delay in early-stage oral squamous cell carcinoma and its relation to survival*. J Craniomaxillofac Surg, 2021. **49**(6): p. 462-467.
56. Römer, P., *Hyperspektralbildgebung zur automatisierten Klassifizierung von oraler Muskulatur, Fett und Mundschleimhaut unter Verwendung eines 6-schichtigen light-weight neuronalen Netzwerks*. 2022, Johannes Gutenberg-Universität Mainz.
57. Chen, S., et al., *The Diagnostic Accuracy of Incisional Biopsy in the Oral Cavity*. J Oral Maxillofac Surg, 2016. **74**(5): p. 959-64.
58. Pentenero, M., et al., *Oral mucosal dysplastic lesions and early squamous cell carcinomas: underdiagnosis from incisional biopsy*. Oral Dis, 2003. **9**(2): p. 68-72.
59. Frydrych, A.M., et al., *Oral cavity squamous cell carcinoma survival by biopsy type: a cancer registry study*. Aust Dent J, 2010. **55**(4): p. 378-84.
60. Kammerer, P.W., et al., *Prospective, blinded comparison of cytology and DNA-image cytometry of brush biopsies for early detection of oral malignancy*. Oral Oncol, 2013. **49**(5): p. 420-6.
61. Macey, R., et al., *Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions*. Cochrane Database Syst Rev, 2015(5): p. CD010276.
62. Kämmerer, P.W., et al., *A chemiluminescent light system in combination with toluidine blue to assess suspicious oral lesions-clinical evaluation and review of the literature*. Clin Oral Investig, 2015. **19**(2): p. 459-66.
63. Zhang, L., et al., *Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome*. Cancer research, 2005. **65**(17): p. 8017-8021.
64. Patton, L.L., J.B. Epstein, and A.R. Kerr, *Adjunctive techniques for oral cancer examination and lesion diagnosis: a systematic review of the literature*. J Am Dent Assoc, 2008. **139**(7): p. 896-905; quiz 993-4.
65. Su, W.W., et al., *A community-based RCT for oral cancer screening with toluidine blue*. J Dent Res, 2010. **89**(9): p. 933-7.
66. Barrellier, P., et al., *[The use of toluidine blue in the diagnosis of neoplastic lesions of the oral cavity]*. Rev Stomatol Chir Maxillofac, 1993. **94**(1): p. 51-4.
67. Rashid, A. and S. Warnakulasuriya, *The use of light-based (optical) detection systems as adjuncts in the detection of oral cancer and oral potentially malignant disorders: a systematic review*. J Oral Pathol Med, 2015. **44**(5): p. 307-28.

68. Koch, F.P., et al., *Effectiveness of autofluorescence to identify suspicious oral lesions--a prospective, blinded clinical trial*. Clin Oral Investig, 2011. **15**(6): p. 975-82.